Patients receiving platinum-based chemotherapy were at higher risk of developing thromboembolism.
In colorectal cancer (CRC) liver metastases, neoadjuvant FOLFOX chemotherapy positively influenced local immune response.
African Americans (AAs) with prostate cancer who have a Gleason score of 3+3=6 produce less prostate-specific antigen.
Imetelstat was active in patients with myelofibrosis, but had the potential to cause clinically significant myelosuppression.
The extent of lymphadenectomy during surgery for esophageal cancer might not influence 5-year all-cause or disease-specific survival.
Risk of sentinel lymph node (SLN) positivity was significantly lower in patients with melanoma with histologic regression.
The use of molecularly targeted agents outside of their indications did not improve progression-free survival in heavily pretreated cancer.
Patients with chronic myeloid leukemia who received a glitazone along with imatinib remained disease-free for up to five years.
An experimental therapy for chronic lymphocytic leukemia that uses a patient's own T cells may cure patients and prolong survival.
There has been an increase in the number of American men with cancer in one breast who have surgery to remove their cancer-free breast.
For biochemically recurrent prostate cancer, treatment with white button mushroom (WBM) powder may reduce prostate-specific antigen (PSA).
The FDA has approved rolapitant (Varubi) in combination with other antiemetic agents for the prevention of delayed nausea and vomiting.
Temozolomide should be considered as a possible first-line treatment for adults with intracranial ependymoma after failure of surgery and radiotherapy.
Statin use may be associated with a decreased risk of pancreatic cancer in patients with type 2 diabetes.
The EMC92-International Staging System (ISS) is a robust novel prognostic tool compared with current markers.
For some pediatric cancer patients with relapsed or refractory cancer, extensive genetic analysis can open up new options.
Adjuvant erlotinib did not prolong-disease-free survival in patients with EGFR-expressing non-small cell lung cancer (NSCLC).
Fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab is a feasible treatment for some with metastatic colorectal cancer (mCRC).
Rates of inpatient palliative care consultation remain low and occur close to death irrespective of race/ethnicity.
Transvaginal sonography (TVS) is comparable to magnetic resonance imaging (MRI) for diagnosing and staging local cervical cancer.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Immunotherapy Combinations for Renal Cell Carcinoma Offer Promise, Challenges
- ASCO Updates Metastatic Lung Cancer Therapy Guideline to Include Targeted Agents, Early Palliative Care
- Association of 21-Gene Recurrence Score Assay, Chemo in Early-stage Breast Cancer
- Sonography, MRI Comparable for Cervical Cancer Staging
- In Cutaneous Melanoma, Early Sentinel-Node Biopsy Associated with Poorer Survival
- Molecular Profiles Can be Used for Early Detection for Aggressive Prostate Cancer
- Thyroid Carcinoma Treatment Regimens
- Combining Aromatase Inhibitors, Bisphosphonates May Benefit Women With Breast Cancer
- Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity
- Better Preoperative Coordination of Care Needed for Patients With Lung Cancer
- New Study Suggests Older Adults Not More Likely to Refuse Cancer Treatment
- Platinum-Based Chemo for Bladder Cancer Linked With Increased Thromboembolism Risk
- Immune Response to Chemo Improves PFS in Colorectal Cancer Liver Metastases
- African American Men With PCa Produce Less PSA Despite Larger Prostates
- Imetelstat Active in Myelofibrosis, But May Cause Myelosuppression
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|